CD274 and cancer: Similar benefits were observed in glioblastoma models, where the combination of CT2A-specific RNA-based cancer vaccines with anti–PD-L1 blockade resulted in an increase in tumor-infiltrating neoantigen-specific T cells and improved survival outcomes [148].